Angiogenesis, Cardiovascular Morbidity, Covid19, Endothelial Dysfunction
Conditions
Keywords
Syndecan-1, Thrombomodulin, VEFG, ANG-2
Brief summary
Severe SARS-CoV-2 disease is characterized by a progressive hypoxemic respiratory failure. Autopsies from these patients show severe endothelial damage with extensive vascular thrombosis, microangiopathy, and occlusion of alveolar capillaries and, finally, evidence of new vessel growth through intussusceptive angiogenesis. This research aims to study endothelial damage and angiogenesis biomarkers and its association with major cardiovascular events.
Detailed description
To study the presence of endothelial damage and angiogenic biomarkers with major cardiovascular events, the investigators will perform an observational study to evaluate plasma biomarkers concentrations in Covid-19 patients hospitalized in critical care units. After ethical review board approval, the investigators will select 40 patients admitted to intensive care units (ICU). After patient written consent or if the participants are unable to consent, after a relative subrogated acceptance, the investigators will collect blood samples in the first 24 hrs and on the 10th day of hospitalization. Venous blood samples are collected. After obtaining all samples, serum Syndecan-1, thrombomodulin, ANG-2, FGF basic, HGF, IL-8, PDGF-BB, TIMP-1, TIMP-2, TNFα y VEGF will be determined by a researcher blinded to the patient using commercially available Elisa kits. The concentration of each biomarker at each sample time will be compared. The investigators will observe clinical outcomes after one, 3, 6, and 12 months after the hospitalization. The investigators found no previous data of this measurement in the COVID-19 scenario. In this observational study, the investigators select a sample size on convenience for the primary outcome.
Interventions
DIAGNOSTIC_TESTEndothelial damage and angiogenic biomarkers
Blood samples for biomarkers study
Sponsors
University of Chile
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Patients older than 18 years 2. Patient with a diagnosis of COVID-19 confirmed by PCR 3. Patient with radiological image suggestive of COVID-19 with pending confirmation 4. Need for ventilatory support with oxygen therapy by HFNC (High-flow nasal cannula) 5. Need for invasive mechanical ventilation.
Exclusion criteria
1. Patient with an image suggestive of COVID-19 with negative PCR 2. Anticoagulation users before admission for any reason.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline Syndecan-1 concentration at 10th day | 24 Hours, 10 Days | Elevation of plasma Syndecan-1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline ANG-2 concentration at 10th day | 24 Hours, 10 Days | Elevation of plasma ANG-2 |
| Change from Baseline FGF basic concentration at 10th day | 24 Hours, 10 Days | Elevation of plasma FGF basic |
| Change from Baseline HGF concentration at 10th day | 24 Hours, 10 Days | Elevation of plasma HGF |
| Change from Baseline IL-8 concentration at 10th day | 24 Hours, 10 Days | Elevation of plasma IL-8 |
| Change from Baseline VEGF concentration at 10th day | 24 Hours, 10 Days | Elevation of plasma VEGF |
| Change from Baseline TNFα concentration at 10th day | 24 Hours, 10 Days | Elevation of plasma TNFα |
| Change from Baseline PDGF-BB concentration at 10th day | 24 Hours, 10 Days | Elevation of plasma PDGF-BB |
| Change from Baseline TIMP-1 concentration at 10th day | 24 Hours, 10 Days | Elevation of plasma TIMP-1 |
| Change from Baseline TIMP-2 concentration at 10th day | 24 Hours, 10 Days | Elevation of plasma TIMP-2 |
| Major cardiovascular events | 1 month, 3 months, 6 months 12 months. | Acute coronary syndrome, myocardial injury, pulmonary embolism, and death. |
| Change from Baseline Thrombomodulin concentration at 10th day | 24 Hours, 10 Days | Elevation of plasma Thrombomodulin |
Countries
Chile
Outcome results
None listed